In summary, the calculation of the ALBI score and determination of peripheral CD3+γδ+Vδ2+PD1+ T lymphocyte cells and CD3+γδ+Vδ2+Tim3+ T lymphocyte cells in patients with advanced HCC are conducive to predicting the efficacy of ICIs and screening patients who may benefit from immunotherapy clinically. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.